Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Paraoxonase 1 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Arylesterase 1, PON 1, Aromatic Esterase 1, A-Esterase 1, K-45, Serum Aryldialkylphosphatase 1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD191279200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-Citrate

Sample Requirements

5 ul/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1.25–80 ng/ml

Limit of Detection

1.1 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 12.1%

Inter-assay (Run-to-Run)

n = 6; CV = 6.2%

Spiking Recovery


Dilution Linearity




  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures PON1 in serum and plasma (citrate)
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cardiovascular disease, Energy metabolism and body weight regulation, Lipoprotein metabolism, Others


Paraoxonase 1 (PON1) is a member of a family of proteins that also includes PON2 and PON3, the genes for which are clustered in tandem on the long arms of human chromosome 7 (q21.22). PON1 belongs to a family of enzymes that catalyze the hydrolysis of a broad range of carboxylic acid esters, carbonates, and lactones, as well as toxic organophosphates, including the insecticide paraoxon.
PON1 is a 355 amino-acid glycoprotein, which is synthesized in the liver and secreted into the blood, where it associates with HDL (high-density lipoprotein). PON1 has a six bladed β-propeller structure reminiscent of DFPases (di-isopropylfluorophosphatases) with a unique active site lid.
PON1 has antioxidative properties, which are associated with the enzyme´s capability to protect LDL, as well as HDL from oxidation, to decrease macrophage oxidative status, to stimulate cholesterol efflux from macrophages, to decrease oxidative status in atherosclerotic lesions, and to attenuate atherosclerosis development.
Concentration and activity of PON1 are highly variable in human populations. PON1 levels can be modified by acquired factors such as diet, lifestyle and disease. A number of studies have shown that PON1 activity decreases with age. Cigarette smoke extract is known to inhibit PON1 activity and alcohol increases PON1 activity.
Most studies have found that PON1 activity is reduced in Type I and Type II diabetic patients. PON1 activity is also lower in patient with the metabolic syndrome, symptoms of which include abnormal fasting glucose levels and increased insulin resistance. Oxidative stress is a known risk factor for the development of dementia. PON1 activity is reportedly reduced in patients with vascular dementia and Alzheimer´s disease, however, it is not known if this is a cause or a consequence of increased oxidation.
Chronic renal failure is associated with elevated oxidative stress, and PON1 activity is consistently lower in patients suffering from renal failure. In one study, PON1 activity was restored to normal levels after kidney transplantation, suggesting that the effect on PON1 activity is a consequence of the disease and nota an underlying cause.
Alterations in PON1 activity have been seen in a number of others disorders, including liver cirrhosis, chronic hepatitis, HDL deficiencies, Gulf War Syndrome and anxiety.

Areas of investigation: Oxidative stress, Energy metabolism

Product References (3)


  • Dougan G, Chatfield S, Pickard D, Bester J, O'Callaghan D, Maskell D.Construction and characterization of vaccine strains of Salmonella harboringmutations in two different aro genes. J Infect Dis. 1988 Dec;158(6):1329-35.PubMed PMID: 3058818. See more on PubMed
  • Gugliucci A, Lustig RH, Caccavello R, Erkin-Cakmak A, Noworolski SM, Tai VW,Wen MJ, Mulligan K, Schwarz JM. Short-term isocaloric fructose restriction lowersapoC-III levels and yields less atherogenic lipoprotein profiles in children withobesity and metabolic syndrome. Atherosclerosis. 2016 Oct;253:171-177. doi:10.1016/j.atherosclerosis.2016.06.048. Epub 2016 Jul 19. PubMed PMID: 27451002. See more on PubMed
  • Kupczyk D, Bilski R, Sokołowski K, Pawłowska M, Woźniak A, Szewczyk-Golec K.Paraoxonase 1: The Lectin-Like Oxidized LDL Receptor Type I and Oxidative Stress in the Blood of Men with Type II Obesity. Dis Markers. 2019 Oct 15;2019:6178017. doi: 10.1155/2019/6178017. eCollection 2019. PubMed PMID: 31737129; PubMedCentral PMCID: PMC6815624. See more on PubMed
Summary References (11)

References to Paraoxonase 1

  • Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005 Feb 15;69 (4):541-50
  • Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004 Nov;107 (5):435-47
  • Ferre N, Feliu A, Garcia-Heredia A, Marsillach J, Paris N, Zaragoza-Jordana M, Mackness B, Mackness M, Escribano J, Closa-Monasterolo R, Joven J, Camps J. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013 Dec;46 (18):1830-6
  • Fuhrman B. Regulation of hepatic paraoxonase-1 expression. J Lipids. 2012;2012:684010
  • Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry. 2005 Sep 6;44 (35):11843-54
  • Graner M, James RW, Kahri J, Nieminen MS, Syvanne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006 Jun 20;47 (12):2429-35
  • Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013 Sep 3;123 (9):3815-28
  • Liang KW, Lee WJ, Lee IT, Lee WL, Lin SY, Hsu SL, Wan CJ, Yu CY, Tsai IC, Fu CP, Ting CT, Sheu WH. Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome. Clin Chim Acta. 2011 Sep 18;412 (19-20):1835-41
  • Rice NE, Bandinelli S, Corsi AM, Ferrucci L, Guralnik JM, Miller MA, Kumari M, Murray A, Frayling TM, Melzer D. The paraoxonase (PON1) Q192R polymorphism is not associated with poor health status or depression in the ELSA or INCHIANTI studies. Int J Epidemiol. 2009 Oct;38 (5):1374-9
  • Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999 Sep;19 (9):2214-25
  • Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000 Jun;150 (2):295-8
Related Products Docs